Biophytis to attend BIO-Europe in Munich

Biophytis announces that the company is attending the BIO-Europe conference which will be held in Munich, Germany, November 6th to 8th 2023. The conference will, as every year, bring together all the players in the pharmaceutical and biotech industries.

As part of the international development strategy for Sarconeos (BIO101) in the treatment of severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy, Edouard Bieth, Chief Business Officer of Biophytis, will meet pharmaceutical industry decision-makers to initiate co-development and commercialization partnerships for the company’s drug candidate. Securing an R&D and commercialization partnership agreement is a strategic objective for Biophytis, in line with its ambition to rapidly bring its lead drug candidate Sarconeos (BIO101) to market in the US, Europe, Asia and South America.